Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMMP Prima BioMed	$1.63 +3.8%	$1.80	$1.32 ▼ $2.72	$229.28M	1.76	205,722 shs	97,910 shs
SLRN Acelyrin	$2.27	$2.29	$1.85 ▼ $7.25	$229.17M	1.07	1.28 million shs	N/A
YMAB Y-mAbs Therapeutics	$4.80 -2.2%	$4.46	$3.55 ▼ $16.11	$222.34M	0.52	303,868 shs	126,155 shs
ZIVO ZIVO Bioscience	$14.91 +4.9%	$16.22	$5.53 ▼ $22.15	$56.85M	0.02	982 shs	516 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMMP Prima BioMed	+3.82%	+1.24%	-18.09%	-12.37%	-41.16%
SLRN Acelyrin	0.00%	0.00%	0.00%	-12.69%	-41.19%
YMAB Y-mAbs Therapeutics	-2.24%	+3.67%	+8.84%	-0.21%	-60.10%
ZIVO ZIVO Bioscience	0.00%	+4.85%	-17.17%	-12.81%	+129.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMMP Prima BioMed	1.3685 of 5 stars	3.5	1.0	0.0	0.0	2.7	0.0	0.0
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	3.45 of 5 stars	4.4	2.0	0.0	0.0	2.7	2.5	0.6
ZIVO ZIVO Bioscience	0.2747 of 5 stars	0.0	2.0	0.0	0.0	1.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMMP Prima BioMed	3.00	Buy	$7.00	329.45% Upside
SLRN Acelyrin	2.40	Hold	$9.60	322.91% Upside
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$15.60	225.00% Upside
ZIVO ZIVO Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZIVO, YMAB, SLRN, and IMMP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$20.00 ➝ $15.00
5/28/2025	YMAB Y-mAbs Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00 ➝ $18.00
5/19/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
5/14/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
5/14/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
4/22/2025	YMAB Y-mAbs Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMMP Prima BioMed	$5.14M	46.31	N/A	N/A	$1.05 per share	1.55
SLRN Acelyrin	N/A	N/A	N/A	N/A	$6.74 per share	N/A
YMAB Y-mAbs Therapeutics	$87.68M	2.48	N/A	N/A	$2.05 per share	2.34
ZIVO ZIVO Bioscience	$15.85K	3,586.87	N/A	N/A	($0.81) per share	-18.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
SLRN Acelyrin	-$381.64M	-$2.69	N/A	N/A	N/A	N/A	-44.12%	-39.02%	8/12/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$29.67M	-$0.64	N/A	N/A	N/A	-31.84%	-30.59%	-22.70%	8/11/2025 (Estimated)
ZIVO ZIVO Bioscience	-$7.78M	-$4.93	N/A	∞	N/A	N/A	N/A	-2,240.92%	8/12/2025 (Estimated)

Latest ZIVO, YMAB, SLRN, and IMMP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	SLRN Acelyrin	-$0.95	-$0.55	+$0.40	-$0.55	N/A	N/A
5/13/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.22	-$0.12	+$0.10	-$0.12	$19.97 million	$20.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMMP Prima BioMed	N/A	18.86	N/A
SLRN Acelyrin	N/A	7.15	7.15
YMAB Y-mAbs Therapeutics	N/A	4.77	4.35
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMMP Prima BioMed	2.32%
SLRN Acelyrin	87.31%
YMAB Y-mAbs Therapeutics	70.85%
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
IMMP Prima BioMed	3.07%
SLRN Acelyrin	13.60%
YMAB Y-mAbs Therapeutics	19.70%
ZIVO ZIVO Bioscience	48.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMMP Prima BioMed	2,021	146.04 million	141.56 million	Optionable
SLRN Acelyrin	135	100.95 million	86.68 million	Optionable
YMAB Y-mAbs Therapeutics	150	45.28 million	36.36 million	Optionable
ZIVO ZIVO Bioscience	10	3.81 million	2.91 million	Not Optionable

ZIVO, YMAB, SLRN, and IMMP Headlines

Recent News About These Companies

ZIVO Bioscience (NASDAQ:ZIVO) Stock Price Passes Below 50 Day Moving Average - What's Next?

June 25 at 5:25 AM | marketbeat.com

ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry

June 20, 2025 | businesswire.com

ZIVO Bioscience (NASDAQ:ZIVO) Stock Price Passes Below 50 Day Moving Average - Here's What Happened

June 17, 2025 | marketbeat.com

ZIVO Bioscience (NASDAQ:ZIVO) Share Price Crosses Above 50-Day Moving Average - Time to Sell?

June 7, 2025 | marketbeat.com

ZIVO Bioscience (NASDAQ:ZIVO) Shares Cross Below 50-Day Moving Average - Should You Sell?

May 30, 2025 | marketbeat.com

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7, 2025 | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6, 2025 | businesswire.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

March 18, 2024 | investorplace.com

Harmony Biosciences Holdings

March 4, 2024 | forbes.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.comM

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.comM

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72

November 1, 2023 | msn.com

Zivo Bioscience Inc ZIVO

November 1, 2023 | morningstar.comM

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

October 30, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO, YMAB, SLRN, and IMMP Company Descriptions

Prima BioMed NASDAQ:IMMP

$1.63 +0.06 (+3.82%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.63 0.00 (0.00%)

As of 04:36 AM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Acelyrin NASDAQ:SLRN

$2.27 0.00 (0.00%)

As of 05/21/2025

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Y-mAbs Therapeutics NASDAQ:YMAB

$4.80 -0.11 (-2.24%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$4.81 +0.01 (+0.19%)

As of 04:01 AM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

ZIVO Bioscience NASDAQ:ZIVO

$14.91 +0.69 (+4.85%)

As of 06/24/2025 02:51 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time